会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 71. 发明授权
    • Method for injection molding of high quality parts
    • 高品质零件注塑成型方法
    • US06287488B1
    • 2001-09-11
    • US09240711
    • 1999-02-02
    • Thomas J. DoughertyThomas C. Dougherty
    • Thomas J. DoughertyThomas C. Dougherty
    • B29C4556
    • B29C45/561B29C2045/567B29L2011/0016B29L2017/005
    • A method and apparatus for injection molding of high quality thermoplastic parts is such that a conventional movable mold half is mounted on a movable platen of the injection molding machine, and a special stationary mold half is mounted on the stationary platen. The stationary mold half includes a stationary plate secured to the stationary platen, with the stationary plate including stationary mold inserts. Each stationary mold insert has a stationary mold insert surface. An A-half parting line plate is movably attached to the stationary plate, with the A-half parting line plate being movable with respect to the stationary plate and the stationary mold inserts. A driving device, such as a hydraulic cylinder, is disposed between the stationary plate and the A-half parting line plate, with the driving device driving the A-half parting line plate toward and away from the stationary plate. A control circuit is provided for controlling the driving device to control a movement of the A-half parting line plate with respect to the stationary plate.
    • 用于注塑成型高品质热塑性部件的方法和装置是这样的:将传统的可移动半模安装在注射成型机的可移动压板上,并且在固定压板上安装特殊的固定半模。 固定模具半部包括固定在固定压板上的固定板,固定板包括固定模具插入件。 每个固定模具插入件具有固定的模具插入表面。 一个半分割线板可移动地连接到固定板上,其中A半分割线板可相对于固定板和固定模具插入件移动。 驱动装置如液压缸设置在固定板和A半分割线板之间,驱动装置驱动A-half分型线板朝向和远离固定板。 提供控制电路用于控制驱动装置以控制半分离线板相对于固定板的移动。
    • 74. 发明授权
    • Alkyl ether analogues of benzoporphyrin derivatives
    • 苯并卟啉衍生物的烷基醚类似物
    • US5498710A
    • 1996-03-12
    • US231113
    • 1994-04-22
    • Ravindra K. PandeyThomas J. DoughertyKevin M. SmithIsabelle Meunier
    • Ravindra K. PandeyThomas J. DoughertyKevin M. SmithIsabelle Meunier
    • C07D487/22
    • C07D487/22
    • Compounds having properties superior to known photosensitizers defined by the following chemical formula: ##STR1## including R groups R.sup.1, R.sup.2, R.sup.3, and R.sup.4, wherein R.sup.1 and R.sup.2 are methyl or --CH(O--(CH.sub.2).sub.n CH.sub.3)CH.sub.3 or are joined together to form the group D and wherein R.sup.3 and R.sup.4 are methyl or --CH(O--(CH.sub.2).sub.n CH.sub.3)CH.sub.3 or are joined together to form the group D; provided that one of R.sup.1 and R.sup.2 or R.sup.3 and R.sup.4 are joined together to form the group D wherein one of the remaining R groups is methyl and one of the remaining R groups is --CH(O--(CH.sub.2).sub.n CH.sub.3)CH.sub.3, where n is an integer of 5 through 7 and group D is: ##STR2## and R.sub.5 is independently at each occurrence --OR.sub.6 where R.sub.6 is lower alkyl of 1 through 7 carbon atoms or R.sub.6 is an amino acid residue.
    • 具有优于以下化学式定义的已知光敏剂的性质的化合物:包括R基团R 1,R 2,R 3和R 4的其中R 1和R 2是甲基或-CH(O-(CH 2)n CH 3) 一起形成基团D,其中R 3和R 4是甲基或-CH(O-(CH 2)n CH 3)CH 3或连接在一起形成基团D; 条件是R 1和R 2或R 3和R 4中的一个连接在一起形成基团D,其中剩余的R基团之一是甲基,其余的R基团之一是-CH(O-(CH 2)n CH 3)CH 3,其中n 是5〜7的整数,D为:< IMAGE> R5各自独立地为-OR 6,其中R 6为1〜7个碳原子的低级烷基或者R6为氨基酸残基。
    • 75. 发明授权
    • Anti-theft battery system for vehicles
    • 汽车防盗电池系统
    • US5404129A
    • 1995-04-04
    • US97795
    • 1993-07-27
    • David J. NovakThomas J. Dougherty
    • David J. NovakThomas J. Dougherty
    • B60R25/04H01M2/34
    • B60R25/24B60R25/04B60R25/045H01M2/341
    • An anti-theft battery system for vehicles includes a control circuit which is connected in the starting circuit and responds to a starting current which exceeds a set point value to interrupt the starting circuit, thereby disconnecting the starter motor from the battery preventing starting of the vehicle, a reset circuit responsive to the control circuit which resets the control circuit after a delay interval to permit the starter motor to be connected to the vehicle battery, and an override circuit for generating an override signal for overriding the control circuit for a preselected interval of time to permit an authorized operator to start the vehicle, the override circuit including a small portable transmitter adapted to be carried by the vehicle operator and a receiver connected to the control circuit.
    • 用于车辆的防盗电池系统包括控制电路,该控制电路连接在启动电路中并且响应于超过设定值的起动电流以中断启动电路,从而将启动电动机与防止车辆启动的电池断开 ,响应于所述控制电路的复位电路,所述复位电路在延迟间隔之后复位所述控制电路以允许所述起动电动机连接到所述车辆电池;以及超控电路,用于产生用于超控所述控制电路的预置间隔的超控信号, 允许授权操作员启动车辆的时间,该超驰电路包括适于由车辆操作员携带的小型便携式发射器和连接到控制电路的接收器。
    • 76. 发明授权
    • Dual lug battery plate construction
    • 双凸耳电池板结构
    • US5149605A
    • 1992-09-22
    • US760930
    • 1991-09-17
    • Thomas J. Dougherty
    • Thomas J. Dougherty
    • H01M2/24H01M2/30
    • H01M2/24H01M2/305
    • The present invention relates to a unique battery arrangement including battery plates having a pair of spaced apart battery lugs for both the positive and negative plates. While being spaced apart, the lugs are located generally adjacent one top edge of the plates; on opposite sides for the positive and negative plate constructions. The straps used to electrically connect the lugs are lower in height than those used on current battery designs, providing excellent current collection, efficient fusion with smaller lugs and resistance to vibration caused by separation of the lugs from the straps. The present invention also features plates having greater plate surface area, improved current carrying capability and reduced voltage drop. A weld element couples straps of like polarity, and in the preferred embodiment, at least a portion of the weld element is located intermediate the ends of the straps.
    • 本发明涉及一种独特的电池装置,其包括具有用于正极板和负极板的一对间隔开的电池接线片的电池板。 在间隔开的同时,凸耳大致相邻于板的一个顶部边缘; 在正极和负极板结构的相对两侧。 用于电连接凸耳的带子的高度低于当前电池设计中使用的带子,提供优异的电流收集,与较小的接线片的高效融合以及由凸耳与带子分离所产生的抵抗振动。 本发明还具有具有更大的板表面积,改善的载流能力和降低的电压降的板。 焊接元件连接相似极性的带,并且在优选实施例中,焊接元件的至少一部分位于带的端部之间。
    • 77. 发明授权
    • Drugs comprising porphyrins
    • 药物包括卟啉
    • US5028621A
    • 1991-07-02
    • US352774
    • 1989-05-16
    • Thomas J. DoughertyWilliam R. PotterKenneth R. Weishaupt
    • Thomas J. DoughertyWilliam R. PotterKenneth R. Weishaupt
    • A61B5/00A61K31/40A61K41/00A61K49/00A61K51/00A61N5/06A61P35/00A61P43/00C07D487/22C07D519/00C09B47/00G02B6/04G02B6/26G02B6/42
    • A61K31/40A61B5/411A61B5/416A61K41/0071A61N5/0601A61N5/062C07D519/00G02B6/262G02B6/4204A61B5/0071A61B5/0084G02B6/4298Y10S607/901
    • To obtain tumor-selective, photosensitizing drugs useful in the localization of neoplastic tissue and treatment of abnormal neoplastic tissue such as tumors, one of two methods is used. In the first method, a hydrolyzed mixture of the products of reaction of hematoporphyrin with acetic acid and sulfuric acid is cycled through a microporous membrane system to exclude low molecular weight products. In the second method, drugs are synthesized or derived from other pyrrole compounds. The drugs (1) include two covalently bound groups, each with four rings, some of which are pyrroles such as phlorins, porphyrins, chlorins, substituted pyrroles, substituted chlorins or substituted phlorins, each group being arranged in a ring structure, connected covalently to another group and have a triplet energy state above 37.5 kilocalories per mole; (2) are soluble in water, forming an aggregate of over 10,000 molecular weight in water and have an affinity for each other compared to serum protein such that 10 to 100 percent remain self aggregated in serum protein; and (3) are lipophyllic and able to disaggregate and attach to cell plasma, nuclear membrane, mitochondria, lysosomes and tissue. The drug obtained by the first method has an empirical formula of approximately C.sub.68 H.sub.70 N.sub.8 O.sub.11 or C.sub.68 H.sub.66 N.sub.8 O.sub.11 Na.sub.4. Neoplastic tissue retains the drug after it has cleared normal tissues and illumination results in necrosis. Moreover, other photosensitizing materials may be combined with a carrier that enters undesirable tissues and cells of the reticular endothelial system such as macrophages. These photosensitizing materials: (1) must have a triplet energy state above 3.5 kilocalories per mole; (2) cannot be easily oxidized; and (3) not physically quench any required energy state. Preferably, this photosensitizing material should be lipophlic.
    • 为了获得肿瘤选择性的光敏药物,可用于肿瘤组织的定位和治疗异常肿瘤组织如肿瘤,使用两种方法之一。 在第一种方法中,血卟啉与乙酸和硫酸的反应产物的水解混合物循环通过微孔膜系统以排除低分子量产物。 在第二种方法中,合成或衍生自其他吡咯化合物的药物。 药物(1)包括两个共价结合的基团,每个具有四个环,其中一些是吡咯,例如卟啉,卟啉,二氢卟酚,取代的吡咯,取代的二氢卟酚或取代的藜芦烯,每个组排列成环结构,共价连接到 另一组,三重态能量每摩尔高于37.5千卡; (2)可溶于水,与血清蛋白质相比,在水中形成了超过10,000分子量的聚集体,并且与血清蛋白质具有亲和力,使得10%至100%在血清蛋白中保持自我聚集; 和(3)是脂蛋白的并且能够解聚并附着于细胞血浆,核膜,线粒体,溶酶体和组织。 通过第一种方法获得的药物具有约C68H70N8O11或C68H66N8O11Na4的经验式。 肿瘤组织清除正常组织后保留药物,照明会导致坏死。 此外,其它光敏材料可以与进入网状内皮系统的不希望的组织和细胞如巨噬细胞的载体组合。 这些光敏材料:(1)必须具有每千克3.5千卡以上的三线态能量状态; (2)不易氧化; 和(3)不能物理地淬灭任何所需的能量状态。 优选地,该光敏材料应该是脂肪族的。
    • 80. 发明授权
    • Drugs comprising porphyrins
    • 药物包括卟啉
    • US4649151A
    • 1987-03-10
    • US609991
    • 1984-05-14
    • Thomas J. DoughertyWilliam R. PotterKenneth R. Weishaupt
    • Thomas J. DoughertyWilliam R. PotterKenneth R. Weishaupt
    • A61B5/00A61K31/40A61K41/00A61K49/00A61K51/00A61N5/06A61P35/00A61P43/00C07D487/22C07D519/00C09B47/00G02B6/04G02B6/26G02B6/42
    • A61K31/40A61B5/411A61B5/416A61K41/0071A61N5/0601A61N5/062C07D519/00G02B6/262G02B6/4204A61B5/0071A61B5/0084G02B6/4298Y10S607/901
    • To obtain tumor-selective, photosensitizing drugs useful in the localization of neoplastic tissue and treatment of abnormal neoplastic tissue such as tumors, one of two methods is used. In the first method, a hydrolyzed mixture of the products of reaction of hematoporphyrin with acetic acid and sulfuric acid is cycled through a microporous membrane system to exclude low molecular weight products. In the second method, drugs are synthesized or derived from other pyrrole compounds. The drugs: (1) include two covalently bound groups, each with four rings, some of which are pyrroles such as phlorins, porphyrins, chlorins, substituted pyrroles, substituted chlorins or substituted phlorins, each group being arranged in a ring structure, connected covalently to another group and have a triplet energy state above 37.5 kilocalories per mole; (2) are soluble in water, forming an aggregate of over 10,000 molecular weight in water and have an affinity for each other compared to serum protein such that 10 to 100 percent remain self aggregated in serum protein; and (3) are lipophyllic and able to disaggregate and attach to cell plasma, nuclear membrane, mitochondria, lysosomes and tissue. The drug obtained by the first method has an empirical formula of approximately C.sub.68 H.sub.70 N.sub.8 O.sub.11 or C.sub.68 H.sub.66 N.sub.8 O.sub.11 Na.sub.4.
    • 为了获得肿瘤选择性的光敏药物,可用于肿瘤组织的定位和治疗异常肿瘤组织如肿瘤,使用两种方法之一。 在第一种方法中,血卟啉与乙酸和硫酸的反应产物的水解混合物循环通过微孔膜系统以排除低分子量产物。 在第二种方法中,合成或衍生自其他吡咯化合物的药物。 药物:(1)包括两个共价结合的基团,每个具有四个环,其中一些是吡咯,例如卟啉,卟啉,二氢卟酚,取代的吡咯,取代的二氢卟酚或取代的藜芦烯,每个组排列成环结构,共价连接 到另一组,并具有高于每摩尔37.5千卡的三线态能量状态; (2)可溶于水,与血清蛋白质相比,在水中形成了超过10,000分子量的聚集体,并且与血清蛋白质具有亲和力,使得10%至100%在血清蛋白中保持自我聚集; 和(3)是脂蛋白的并且能够解聚并附着于细胞血浆,核膜,线粒体,溶酶体和组织。 通过第一种方法获得的药物具有约C68H70N8O11或C68H66N8O11Na4的经验式。